The Institute of Medicine (IOM) recently convened a committee to review the effects of sodium intake on health outcomes other than blood pressure, focusing on intake from 1500 to 2300 mg/24hr. 1 While the final report supported population-wide efforts to lower sodium, it concluded that there were insufficient data to support a lowering of sodium to <1500 mg/24hr, as recommended by the American Heart Association, 2, 3 or to <2000 mg/24hr, as recommended by the World Health Organization. 4 The 2010 Dietary Guidelines for Americans 5 recommend lowering sodium to <1500 mg/24hr for a majority of adults and to <2300 mg/24hr for all others.
Several observational studies 6 as well as randomized trials 7, 8 have examined the associations of sodium and subsequent morbidity and mortality, and generally suggest a lowering of risk with lower sodium. However, few studies have examined absolute levels of sodium intake down to those considered in the IOM report.
Some recent studies have raised the possibility of adverse effects of very low sodium intake on cardiovascular disease (CVD). Data from the FLEMENGHO and EPOGH cohorts found a higher level of CVD mortality among those in the lowest tertile of sodium. 9 In addition, data from patients with CVD or diabetes suggested a J-shaped curve, with an increase in risk of CVD and of mortality at both the upper and lower levels of sodium intake. 10, 11 The IOM concluded, however, that these data were limited and their quality was insufficient to support the assertion of an adverse effect on CVD at very low levels of sodium intake. All of the studies reporting a paradoxical inverse or J-shaped association between sodium intake and CVD were based on secondary analyses of studies that were not designed to assess this relationship. Major concerns included suboptimal measurement of sodium and the potential for bias due to indication or reverse causality. Most studies with urinary sodium excretion collected only a spot or single 24-hour urine specimen or included a high percent of participants with a pre-existing illness.
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Phases I and II of the Trials of Hypertension Prevention (TOHP) collected multiple 24- hour urine specimens over periods of either 18 months 12 or 3-4 years. 13 To represent long-term usual intake of sodium, these measures were averaged among those not on an active sodium intervention. In extended follow-up, a linear association of the sodium-potassium ratio with CVD was identified.
14 Sodium also showed a linear association, of borderline significance, with CVD. The current report provides more detail on the relationship of sodium to CVD, particularly at the low absolute sodium intake levels considered by the IOM. It also provides more detail regarding the quality of the 24-hour urine collections, particularly the relationship of sodium and creatinine, and the impact of the latter on the association of sodium with CVD.
Methods

TOHP Trials
The TOHP Follow-up Study was an observational follow-up of TOHP, Phases I and II, and has been described previously. 14 TOHP I took place from September 1987 to January 1990, and evaluated the effects of four supplement and three lifestyle interventions, including weight loss and sodium reduction interventions, on blood pressure in 2,182 men and women aged years with high normal blood pressure. 12 Those in the active sodium reduction intervention were excluded from the current analyses, leaving 1855 eligible TOHP I participants. In TOHP II, which took place from December 1990 to March 1995, the effects of sodium reduction and weight loss on blood pressure were tested over a longer 3-4 year follow-up period in a two-bytwo factorial design among 2,382 pre-hypertensive men and women age 30-54. 13 Eligible participants had a body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) representing 110% to 165% of desirable body weight. Those in the active
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During the trial periods, three to seven 24-hour urine collections were scheduled over 18 months in TOHP I and over three to four years in TOHP II. Usual intake of sodium or potassium or their ratio was calculated as the mean of available urinary excretion measures at 5 (lifestyle interventions) or 7 (nutritional supplement interventions) scheduled collections during 18 months in TOHP I and at 3 or up to 5 scheduled collections during 3 years in TOHP II. Mean sodium and potassium excretions, representing usual intake, were computed over all collections among pre-hypertensive individuals not in the sodium reduction intervention. All of the urinary sodium and potassium measures were expressed as mg/24hr. To explore whether the relationships could be affected by under-collection, measures of creatinine were computed over the same collections, along with the creatinine-to-weight ratio (Cr/Wt), the sodium-to-creatinine ratio (Na/Cr), the potassium/creatinine ratio (K/Cr), and the sodium/potassium ratio (Na/K).
TOHP Follow-up
The observational follow-up for CVD began in 2000, approximately 10 years after the end of TOHP I and 5 years after the end of TOHP II, and included a total of 4,526 TOHP I and II participants (with 38 participating in both TOHP I and TOHP II) (Figure 1 ). Of these, 2,974
were not in a sodium reduction intervention, had available sodium excretions, and remained alive and CVD-free at the end of the trial periods. The follow-up was conducted centrally by mail and phone from the TOHP coordinating center at the Brigham and Women's Hospital, Boston, Massachusetts, and was approved by institutional review boards there and at the participating clinic centers. Follow-up questionnaires focused on collection of CVD endpoints that had occurred following the conclusion of the trials. Additional questionnaires were sent at two-year and potassium measures were expressed as mg/24hr. To explore whether the rela la at t tion on o sh sh ship ip ips s s co co cou uld be affected by under-collection, measures of creatinine were computed over the same collections al lon on ng g g wi wi with th th t t the he h c cre re rea at atinine-to-weight ratio (Cr/Wt t t) ), ), th h he sodium-to--cr cr c eati ti ini ni nin n ne ratio (Na/Cr), the pota a ass s ium/crea eati ti tini nine ne r r rat atio io io ( ( (K/ K/ K/C Cr Cr), ) a a and nd n th h he so o od dium m m/p p pota as ass si sium um m r rat ati io io ( (Na Na/K /K /K). ).
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The primary endpoint for the follow-up study was CVD or CVD death, including myocardial infarction (MI), stroke, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), or death from cardiovascular disease. Upon notification of occurrence of a primary nonfatal endpoint, consent was sought to obtain medical records. These were reviewed by a study physician, blinded to the participant's intervention assignment, to confirm the reported events. Table 1 ).
Statistical analysis
As described above, sodium levels were averaged across all collections during the course of the trial periods in those not in an active sodium intervention who remained alive and CVD-free at the end of the trial periods. Absolute levels were grouped into categories defined as <2300, 2300
to <3600, 3600 to <4800, and 4800 mg/24hr or higher, where 2300 represents current guideline recommendations for adults, 5 and 3600 represents the median sodium intake in the US population aged 31-50. 15 Baseline characteristics were expressed as percents or means, and were tested for trend over sodium categories using chi-square statistics or regression analysis. Cox regression models estimated the hazard ratio (HR) for the linear effect of sodium and for the defined above. The baseline hazard was stratified by trial and those who were in both phases contributed time to the end of TOHP I until entry into TOHP II as well as any follow-up from the end of TOHP II. Models were adjusted for clinic, age, sex, race/ethnicity, and other treatment assignments (model 1), additionally for education, baseline weight, alcohol use, smoking, exercise, potassium excretion, and family history of cardiovascular disease (model 2), and also for changes in weight, smoking, and exercise during the trial periods (model 3), as prespecified. 14 Penalized splines with four degrees of freedom were fit using SPlus to examine linearity of effect; 16 introducing more flexibility did not alter the relation in the lower range of sodium.
We also conducted several sensitivity analyses controlling for Cr/Wt in the multivariable models to adjust for potential inadequacy of the urine collections. First, we estimated the withinperson variability of measures of creatinine (mg/24hr) divided by weight in kilograms (Cr/Wt) using mixed effects models. The coefficient of variation (CV) was computed for each participant. We then conducted analyses that excluded those with CV's of 20% or higher and of 30% or higher. In addition, we ran models controlling for Cr/Wt or the CV of Cr/Wt in the model. 17, 18 Finally, we ran models including sodium, potassium, and Cr/Wt in the same models, as well as Na/Cr, K/Cr, and Cr/Wt. These were expressed per standard deviation (SD) for easier comparison of effect sizes. All analyses were conducted in SAS version 9.2, except as noted.
Results
Baseline levels
Sodium and other excretion data were averaged across all measures during the trial periods, with odium.
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in TOHP I and II, respectively, in men and of 2869 and 3340 mg/24hr, respectively, in women.
Characteristics of participants by absolute level of sodium excretion are provided in Table 1 . Those with the lowest sodium levels were more likely to be college educated, more likely to drink alcohol and to exercise at least once/week, although these relationships were less consistent in women. Weight was directly correlated with sodium intake, though change in weight during the trial periods was not. Blood pressure levels, which were restricted during enrollment due to eligibility criteria, were not correlated with sodium levels.
Baseline urinary excretion levels are shown in Table 2 by phase and gender. Median potassium excretion was 2327 mg/24hr, and was higher in men (2502 mg/24hr) than women (1952 mg/24hr), but similar by phase. Median creatinine was 1569 mg/24hr, again higher in men (1726 mg/24hr) than women (1155 mg/24hr). The median creatinine/weight ratio was 19.3 in men and 15.0 in women. Both potassium and creatinine, as well as Cr/Wt, Na/K, and Na/Cr, were positively associated with average sodium excretion.
We computed the coefficients of variation for the Cr/Wt data, using the within-person standard deviation. These were slightly higher in women and in TOHP II, with medians of 18%
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Association with CVD
During the post-trial follow-up, 193 cardiovascular events or CVD deaths occurred. First events included 68 MIs, 77 coronary revascularizations, 22 strokes (1 participant reported both MI and stroke), and 27 CVD deaths. Crude proportions developing CVD were lowest in the two lower sodium excretion groups in each phase ( Table 3 ). In models adjusted for clinic, treatment assignment and demographic variables (model 1), for these plus baseline covariables (model 2), and additionally for changes in weight, smoking and exercise over the trial periods (model 3),
there was a non-significant trend of increasing risk with increasing sodium level. In the fully adjusted model, compared to those with sodium 3600 to <4800 mg/24hr, risk for those with sodium <2300 mg/24hr was 32% lower after multivariable adjustment (p for trend = 0.13). When sodium was considered as a continuous term, risk increased linearly, with a 17% increase in risk per 1000 mg/24hr (p=0.054) in the fully adjusted model.
The spline plot ( Figure 2 ) supports a linear association of sodium with CVD (P=0.044), with a p value for nonlinearity = 0.76. In particular, the curve continues to descend from 3600 to 2300 and 1500 mg/24hr, although the data are sparse at the lowest levels. In this nonlinear curve, compared to those consuming 3600 mg/24hr, the estimated HRs for those consuming 2300 and 1500 mg/24hr were 0.78 and 0.69, respectively.
To determine the impact of differences in creatinine levels on the association of sodium and CVD, we conducted several sensitivity analyses ( Table 4) . We first excluded all those with a CV for Cr/Wt of 20% or greater, leaving a sample size of 1298 participants. The association of sodium with CVD was slightly stronger, with hazard ratios that were 33% lower in those <2300 mg/24hr and 35% higher in those 4800 mg/24hr, but the trend was not statistically significant.
The linear trend also increased to a 20% increase in risk per 1000 mg/24hr (p=0.09). When odium <2300 mg/24hr was 32% lower after multivariable adjustment (p for tren n nd d d = = = 0 0. 0. 13 13 13 For easier comparison, we further considered the excretion variables expressed per standard deviation (Supplemental Table 2 ). The average creatinine/weight ratio was not a predictor of CVD by itself, with a small 4% increase in risk per SD (p=0.72). When the first baseline measure of Cr/Wt was used, rather than the average over the trial period, however, the risk increased by 20% per SD (p=0.0087) (data not shown). The risk of CVD increased by 21%
per SD of average sodium excretion (p=0.05) and decreased by 15% per SD of average potassium excretion (p=0.12), with little change after adjustment for Cr/Wt. Similar results were seen using the sodium/ creatinine and potassium/creatinine ratios.
Discussion
An extensive body of information documents the presence of a direct relationship between sodium intake and blood pressure. During the past year, three new meta-analyses of randomized, controlled clinical trials were published. [19] [20] [21] Although they differed in their trial inclusion and exclusion criteria, each of the meta-analyses reported a significant and clinically important decrement in blood pressure following a reduction in sodium intake. Consistent with prior knowledge, the reduction in blood pressure was greater in those with a higher starting level of blood pressure, older persons, African-Americans, and those with a more successful intervention.
In the meta-analyses that are most generalizeable to clinical practice and public health, 17, 19 total cholesterol and catecholamine levels were essentially unchanged and changes in urinary protein excretion were consistent with a beneficial effect of sodium reduction. Blood pressure is one of potassium excretion (p=0.12), with little change after adjustment for Cr/Wt. Sim mi il ilar r r res es esul ul ults ts ts w w wer e e een using the sodium/ creatinine and potassium/creatinine ratios. . Du Du D ri ri ring ng ng t t the he he p p pa ast st st y y yea ea e r, r, , t t thr hr hree ee e n n new ew e m m met et eta-a-a an an anal al a ys ys yses es es o o of f f ra ra r ndomized d, , the best validated surrogate markers for CVD, [22] [23] [24] and has been identified as one of the leading preventable causes of death in the U.S. 25 Direct observations of the relationship between sodium reduction and CVD are more limited, especially at lower absolute levels of sodium intake. A preponderance of reports based on observational epidemiology support the presence of a direct relationship between sodium intake and CVD, especially for stroke. 26 While the DASH-Sodium clinical trial demonstrated an increasingly beneficial effect of reduced sodium intake on blood pressure at progressively lower levels of dietary sodium down to 1500 mg/day, 27 some reports have identified null, inverse or Jshaped relationships with CVD. 26 In its most recent review of dietary sodium, 1 the IOM committee was charged with examining the effects of very low levels of sodium intake in the range of 1500-2300 mg/day on health outcomes, defined as clinical CVD events. This and other reviews have uniformly concluded that the underlying data showing adverse effects of sodium in this range are of insufficient quality to support a firm conclusion. 1, 19, 26 Many suffer from some combination of potential for bias in the assessment of sodium intake, reverse causality, residual confounding and random error. Despite this, the reports of a paradoxical inverse or J-shaped association between sodium intake and CVD have received considerable media 28, 29 as well as scientific community attention [30] [31] [32] and have been the basis for addition of sodium to food products. 33 Several analyses of CVD or total mortality were based on NHANES data, which employed a single 24-hour diet recall to estimate sodium intake. This approach underestimates sodium intake by failing to measure sodium added at the table, in the kitchen, in supplements, or in drinking water. Falsely low estimation due to underreporting of food and beverage intake and portion sizes is also a concern. Finally, inaccuracies can result from changes in commercial food
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In its most recent review of dietary sodium, 1 the IOM committee was cha ha arg rged ed e w w wit it ith h h examining the effects of very low levels of sodium intake in the range of 1500-2300 mg/day on The gold standard for sodium assessment in healthy persons is 24-hour urine collection.
Overnight and spot urine samples are less burdensome for study participants and research staff.
However, they are affected by diurnal variation, and the methods supporting the validity of their use are inadequate. They represent a weak substitute for 24-hour urine collections, especially when they are used to estimate sodium intake and relationships in an individual. 26 Despite being considered the gold standard, even 24-hour collections are subject to quality control concerns, particularly under-collection of urine specimens. Measurements based on a single 24-hour urine fail to capture day-to-day variability, making them less than optimal for study of the withinperson relationship between sodium and CVD.
The TOHP Follow-up Study used an average of 3-7 carefully collected 24-hour urine collections as a measure of sodium exposure, greatly reducing bias due to measurement error and random error due to within-person variability over time. We found a continued decrease in CVD events among those with sodium levels as low as 1500 mg/day, with no evidence of a J-shape when examining spline curves. Risk reductions among those at the lowest levels of sodium excretion were substantial, with a 32% reduction among those excreting less than 2300 mg/day, although this was not statistically significant due to small numbers in this subgroup and limited power.
To further consider the quality of urine specimens, we also adjusted for creatinine using when they are used to estimate sodium intake and relationships in an individual. . collected an incomplete 24-hour specimen. They may be less likely to exhibit healthy behaviors and more likely to have poorer health outcomes. Creatinine level, however, is also related to other factors, such as age, race, and BMI. 17 While average sodium levels in TOHP were positively associated with creatinine levels and the Cr/Wt ratio, these had little impact on the relationship between sodium and CVD in these analyses.
In our study, the average Cr/Wt was not a predictor of CVD. However, when using only the first baseline urinary excretion, it was a strong predictor. This suggests that using the average for many measurements over several years, as in these TOHP analyses, adjusts for variations in dilution and removes any effect of under-collection, as well as reducing within-person variability. Estimates based on a single urine collection, however, may be distorted by undercollection of the specimen, 9,34 and in such a circumstance creatinine adjustment should be considered.
Reverse causation is another important source of error in observational studies of the relationship between dietary sodium and CVD. This is most likely an issue in studies that include patients with heart failure, coronary heart disease, chronic kidney disease, diabetes mellitus, or even hypertension. Such patients are likely to reduce their sodium intake either because of a poor diet or health advice. This can result in an inverse relationship between sodium intake and CVD that is a consequence of their underlying disease rather than the lower intake of dietary sodium (reverse causation). In many of these studies the situation is further compounded by the use of potent diuretics and other medications that can distort estimates of sodium intake. Often, the he first baseline urinary excretion, it was a strong predictor. This suggests that u usi s sing ng n t t the he he a a ave ve vera rage g for many measurements over several years, as in these TOHP analyses, adjusts for variations in di ilu lu uti ti tion on on a and nd nd r r rem mov ov oves e any effect of under-collecti ti tion on on, as well as red ed duc u in n ng g g w wi w thin-person v vari i iab a ility. Est stim im ima at tes es b ba as ased ed ed o o on n n a a si si sin ng ngl le e u u urine e c c colle e ec ct tion, n, n, h ho ow wev eve e er, ma may y y b be e d d dis is ist to tort rted ed ed b b by y un un nd de der r-r co oll ll llec ec cti ti tion on o o of f f th the e sp p pec eci im imen en, 9,3 ,3 34 a a and nd nd i i in n n su su uch ch ch a a a cir ir ircu cu cums ms m ta a anc nc nce e e c cr crea ea eati ti t n n nine ne ne a ad d dju us ustm tm men en nt t sh sh ho o ould d d b b be e considered.
by guest on April 22, 2017 http://circ.ahajournals.org/ Downloaded from number of CVD events in these studies is small so that even a trivial number of events resulting from reverse causation can distort the results. Eliminating early periods of follow-up and controlling for illness in the analysis may not be a sufficient remedy. Indeed, controlling for blood pressure, hypertension, or hypertension medication in the analysis may eliminate the indirect effect of sodium through blood pressure, which may be the main biologic mechanism. 35 A major strength of the TOHP follow-up analyses is that the cohorts were restricted to healthy, free living prehypertensive individuals who were not taking blood pressure medications. Thus reverse causation is very unlikely to have been an issue in the TOHP follow-up study. However, since it did not include those with high blood pressure, it could also have eliminated those who were most sensitive to the effects of sodium on blood pressure, and in whom the impact on CVD could be even stronger.
Limitations of the current analyses should also be considered. First, the response rate to the TOHP follow-up questionnaires was less than 80%. However, much of this was due to changes in address after 5-10 years of no contact; the response rate was 85% among those with a valid address. We also collected information on cardiovascular deaths for all participants through the NDI. In addition, there was no difference in response by sodium level, reducing the likelihood of bias. Second, it is unclear if sodium levels were maintained throughout follow-up.
However, this concern is shared by most observational studies, and our repeat 24-hour urine collections over 1-4 years represent very accurate assessments of usual sodium intake. Third, we cannot rule out residual confounding. Those on a low sodium diet may exhibit other healthy lifestyle behaviors, including better diet quality and increased exercise. We adjusted for weight, exercise and smoking in our models, as well as changes in these during the intervention periods, but uncontrolled confounding remains a possibility.
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